Form 4: Acrivon Execs' Stock Withholding for Taxes

Acrivon Therapeutics' CEO and EVP reported shares withheld for tax obligations upon restricted stock unit vesting.

Summary

• Peter Blume-Jensen, President and CEO, and Kristina Masson, EVP Business Operations, both Directors of Acrivon Therapeutics, Inc. (ACRV), reported changes in their beneficial ownership.
• On August 14, 2025, shares of Common Stock were withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• Peter Blume-Jensen disposed of 59,766 shares directly at a price of $1.39 per share, retaining 2,146,345 shares in direct beneficial ownership.
• Kristina Masson disposed of 490 shares indirectly at a price of $1.39 per share, retaining 315,196 shares in indirect beneficial ownership.
• The filing clarifies that Dr. Masson disclaims beneficial ownership of shares held by Dr. Blume-Jensen except to the extent of her pecuniary interest, and vice versa, due to their spousal relationship.

Sentiment

Score: 5

Explanation: The filing reports a routine transaction for tax withholding upon RSU vesting, which is a standard part of executive compensation and does not indicate significant positive or negative operational or financial news.

Positives

• Vesting of restricted stock units indicates executives are receiving compensation, aligning their interests with shareholders.

Negatives

• Executives disposed of shares, reducing their direct and indirect holdings, albeit for tax obligations.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The filing clarifies beneficial ownership between Dr. Peter Blume-Jensen and Dr. Kristina Masson, who are spouses, noting disclaimers of beneficial ownership except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: Minor reduction in executive direct/indirect ownership due to tax withholding, but indicates RSU vesting as part of compensation.
• Employees: Not directly impacted beyond the executives involved in the transaction.

Key Dates

Recommendation

This Form 4 filing details a routine transaction where shares were withheld for tax purposes upon the vesting of restricted stock units for two key executives. Such transactions are standard compensation events and do not typically signal a change in the company's fundamental outlook or performance, thus warranting a 'hold' recommendation.

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Tax Withholding, Beneficial Ownership